Ann: Milestone update, page-2

  1. 1,206 Posts.
    lightbulb Created with Sketch. 116
    Well this is a good announcement for Invion 103. So to date, Invion will now have recieved/reviewed data from 32 patients. The fact that they are awaiting on final data from the last cohort is very encouraging. If they hadn't seen any biological effect from patients dosed with CPN10 in the last 2 cohorts, or if there were any adverse effects from the drug, they wouldn't be keeping enrolement open for the final cohort. Exciting few weeks ahead.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.6¢
Change
0.000(0.00%)
Mkt cap ! $8.199M
Open High Low Value Volume
9.6¢ 9.8¢ 9.6¢ $3.656K 38.07K

Buyers (Bids)

No. Vol. Price($)
2 20756 9.6¢
 

Sellers (Offers)

Price($) Vol. No.
9.9¢ 146502 2
View Market Depth
Last trade - 15.11pm 07/08/2025 (20 minute delay) ?
IVX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.